◼ Archived
Business
🔮 holds ✗
FDA Panel Votes In Favor of Replimune’s Melanoma Treatment
Replimune shares surge following a favorable FDA advisory panel vote for its melanoma treatment.
Biotech
32 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
🔮 fades ✗
MapLight shares sink on mixed ph. 2 schizophrenia readout
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
FDA scientists are disputing efficacy claims regarding Capricor Therapeutics' Phase 3 Duchenne muscular dystrophy cell therapy, triggering a stock plunge.
◼ Archived
Business
🔮 holds ✗
Argenx to Buy Forte Biosciences for $2.2 Billion
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
Trump Administration Live Updates: F.D.A. Advisers Hold More Meetings on Poorly Understood Peptides
FDA advisers vote to loosen rules on poorly understood peptides, sparking talk of a biotech gold rush.
◼ Archived
Business
🔮 fades
Why Arrowhead Shot Sky-High, While Chief Rival Ionis Toppled
Arrowhead stock surges to multi-year highs following a major Phase 3 trial success, while chief rival Ionis falls.
◼ Archived
Business
🔮 fades
The 'Surprisingly Soft' Unit That Caused Danaher To Plummet
Danaher shares plummeted up to 14% following Q2 results, as a 'surprisingly soft' business unit overshadowed a beat in earnings and revenue.
◼ Archived
Business
🔮 fades
Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
Tempus AI is acquiring cancer-monitoring firm Personalis in a deal valued at approximately $1.5 billion, though market reaction has been negative.
◼ Archived
Business
🔮 fades
Kalshi Will Offer Sports-Style Betting on Drug Trial Results
Prediction market Kalshi is expanding its platform to allow users to wager on biotech clinical trial outcomes and FDA regulatory decisions.
◼ Archived
Business
🔮 fades
Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports
Eli Lilly is entering the psychedelic drug market with a deal to acquire AtaiBeckley for up to $3.8 billion to treat resistant depression.
◼ Archived
Business
🔮 fades
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits
Celcuity shares plummeted double digits despite the FDA granting the company its first-ever drug approval for advanced breast cancer treatment.
◼ Archived
Business
🔮 fades
Biogen defends anti-tau drug after stock slides on Alzheimer’s readout
Biogen defends its anti-tau drug following a stock decline triggered by a recent Alzheimer's treatment readout.
◼ Archived
Business
🔮 fades
Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors
Q32 Bio (QTTB) shares surged following positive phase 2 clinical trial results for its alopecia areata drug, Bempikibart.
◼ Archived
Business
🔮 fades
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Novo Nordisk and Vivani are partnering to develop a long-acting semaglutide implant designed to improve weight loss adherence for up to a year.
◼ Archived
Business
🔮 fades
Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles
Vertex Pharma's $10 billion purchase of Crinetics sparks a near‑doubling of its shares and a biotech‑M&A surge
◼ Archived
Business
🔮 fades
Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 holds
Novartis to Buy Myricx Bio for Up to $1.5 Billion
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades
How a new fungal genome-editing tool could open fresh paths to cancer treatments
A prime‑editing tool for filamentous fungi is producing novel anti‑cancer compounds, drawing biotech attention.
◼ Archived
Business
🔮 fades
Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Scribe Therapeutics seeks $75 million in an IPO, testing market appetite for early-stage biotech.
◼ Archived
Health
🔮 fades
‘World’s most contagious disease’ on track for highest US cases in 35 years
Measles cases in the United States have surpassed 2,000 in 2026, threatening the nation's measles-free status as infections reach a 35-year high.
◼ Archived
Business
🔮 holds
FDA’s top gene therapy regulator is leaving his role
11 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 holds
FDA to launch pilot program to speed up early-stage clinical trials
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
Biotech Goes Sky-High After LSD Drug Treats Depression
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics to expand its immunology drug portfolio.
◼ Archived
Business
🔮 fades
AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
Why Biotech Stocks Are Celebrating This Nail-Biter
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
FDA panel considers a first-of-its-kind flu vaccine using mRNA technology
An FDA advisory committee has unanimously backed Moderna's mRNA-based flu vaccine, marking a significant development for the technology.
◼ Archived
Business
🔮 holds
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
The Surprising FDA View That Sent Moderna Stock Flying
Moderna stock prices increased following positive feedback from the FDA regarding the company's mRNA influenza vaccine candidate.
◼ Archived
Business
🔮 fades
‘I wouldn’t call it a blip’: Biotech IPOs here to stay after another record-breaking listing
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 holds
Parabilis now the largest VC-backed biotech IPO
Parabilis Medicines’ $745M IPO redefines biotech funding—now the largest VC-backed debut in history.